Generation of HIV-1 and Internal Control Transcripts as Standards for an In-House Quantitative Competitive RT-PCR Assay to Determine HIV-1 Viral Load by Armas Cayarga, Anny et al.
SAGE-HindawiAccess to Research
Biotechnology Research International
Volume 2011, Article ID 964831, 10 pages
doi:10.4061/2011/964831
Research Article
GenerationofHIV-1and InternalControl Transcripts as
Standardsforan In-HouseQuantitativeCompetitive RT-PCR
AssaytoDetermine HIV-1ViralLoad
Anny ArmasCayarga,1 Yenitse Perea Hern´ andez,1 Yaim´ eJ .Gonz´ alezGonz´ alez,1
SantiagoDue˜ nas Carrera,2 Idania Gonz´ alezP´ erez,1 andRen´ eR o b ai n a´ Alvarez1
1Molecular Biology Department, Centro de InmunoEnsayo (CIE), Calle 134 y Avenida 25 Playa, Apartado Postal 6653,
Ciudad de la Habana, CP 11600, Cuba
2HCV Department, Vaccine Division, Centro de Ingenier´ ıa Gen´ etica y Biotecnolog´ ıa (CIGB), Apartado Postal 6653,
Ciudad de la Habana, CP 10600, Cuba
Correspondence should be addressed to Anny Armas Cayarga, anny.armas@yahoo.com
Received 10 January 2011; Revised 19 April 2011; Accepted 27 April 2011
Academic Editor: Gabriel A. Monteiro
Copyright © 2011 Anny Armas Cayarga et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Human immunodeﬁciency virus type-1 (HIV-1) viral load is useful for monitoring disease progression in HIV-infected
individuals. We generated RNA standards of HIV-1 and internal control (IC) by in vitro transcription and evaluated its
performance in a quantitative reverse transcription polymerase chain reaction (qRT-PCR) assay. HIV-1 and IC standards were
obtained at high RNA concentrations, without DNA contamination. When these transcripts were included as standards in a qRT-
PCR assay, it was obtained a good accuracy (±0.5log 10 unit of the expected results) in the quantiﬁcation of the HIV-1 RNA
internationalstandardandcontrols.The lower limitdetection achieved using thesestandards was 511.0IU/mL. Ahigh correlation
(r = 0.925) was obtained between the in-house qRT-PCR assay and the NucliSens easyQ HIV-1 test (bioMerieux) for HIV-1
RNA quantitation with clinical samples (N = 14). HIV-1 and IC RNA transcripts, generated in this study, proved to be useful as
standards in an in-house qRT-PCR assay for determination of HIV-1 viral load.
1.Introduction
The quantitation of human immunodeﬁciency virus type-
1 (HIV-1) RNA is a crucial factor to help clinicians decide
whether to stop or continue antiretroviral combinations
after switching or starting antiretroviral drug therapy [1].
In addition, it is a useful biological marker to study HIV
dynamics [2, 3], host/virus interaction, HIV evolution, and
theprogression oftheacquiredimmunodeﬁciencysyndrome
(AIDS) [4, 5].
There are three major methodologies available for viral
load quantitation. The reverse transcriptase-polymerase
chain reaction (RT-PCR), the nucleic acid sequence-based
ampliﬁcation (NASBA) and a signal ampliﬁcation method-
ology termed branched-chain DNA (bDNA) technique [6].
In the past recent years there have been new reported viral
load assays that have incorporated the real-time detection,
such as the COBAS TaqMan HIV-1 test from Roche Diag-
nostics [7], which utilizes real-time PCR technology [8]a n d
the NucliSens EasyQ HIV-1 from bioMerieux, which uses
molecular beacon for ther e a l - t i m ed e t e c t i o n[ 9]. In spite of
the advantages that oﬀer the use of the real-time PCR, which
helps reducing the possibility of contamination, increasing
the assay sensitivity, and improving the turnaround time
[10], commercially available real-time PCR assays are just
as expensive as the more standard nucleic acid viral load
tests and also rely on expensive, often dedicated equipment,
that can only be used for these assays [10, 11]. For this
reason, inexpensive and technologically simpler assays are
still needed in resource-limited countries, where the new
technology and equipments are currently not available.
Forthedevelopmentofanin-house quantitativecompet-
itive RT-PCR assay (qRT-PCR) for the estimation of HIV-1
viral load, it is necessary to obtain an HIV-1 RNA external2 Biotechnology Research International
Table 1: Sequences of the primers and probes used in this study.
Code Polaritya Primer or probe sequence (5  to 3 )S o u r c e
Primer HIV1-Q3 + CTCAATAAAGCTTGCCTTGA [15]
Primer HIV1-Biot-Q4 − GGGCGCCACTGCTAGAGA [15]
Primer IC-1 + CTCAATAAAGCTTGCCTTGATAGTTGAATTGAAAGTGC This study
Primer IC-2 − GGGCGCCACTGCTAGAGAATAGTGTCGCCCACGTTTAC This study
T7 promoter primer + TAATACGACTCACTATAGGG [16]
Probe HIV1-S None AGTAGTGTGTGCCCGTCTGT [15]
Probe IC-S1 None TAGTTGAATTGAAAGTGCCCGACAT This study
aPolarity: (+) sense, (−)a n t i s e n s e .
control (calibration curve) and an internal quantitation con-
trol (IC),which isaddedto thespecimen at a known concen-
tration before RNA extraction. The IC can be diﬀerentiated
from the viral target sequences and serves to compensate for
variability in RNA extraction and also to indicate substances
in serum or plasma that may be inhibitory to PCR ampliﬁca-
tion [12].
Although chemical synthesis up to a length of about
80 nucleotides is possible, yields decrease rapidly and costs
become prohibitive. A good alternative is to produce the
RNAbyin vitro transcription with T7 RNApolymerase [13].
RNA synthesis by in vitro transcription using phage T7 RNA
polymerase allows preparation of milligram quantities of
RNA for biochemical, biophysical, and structural investiga-
tions [14].
In this study, we generated RNA standards with HIV-1
and internal control sequences, using in vitro transcription
method and evaluated its performance in a qRT-PCR for
determining HIV-1 viral load.
2.Materialsand Methods
2.1. RNA Isolation. RNA was extracted from 200µLo f
human serumor plasma by the guanidinium isothiocyanate-
acid phenol method [17] with modiﬁcations [18]. The RNA
pellets were resuspended in 20µLo fd i e t h y l p y r o c a r b o n a t e -
(DEPC-) treated water.
2.2. Ampliﬁcation of HIV-1 RNA by RT-PCR. Af r a g m e n to f
120bp located in the 5  LTR region of the HIV-1 genome
was ampliﬁed from RNA isolated from an HIV-1 subtype-
B-infected serum, by RT-PCR. The cDNA synthesis by RT
and ampliﬁcation by PCR were carried out in a single tube
in a reaction mixture of 25µLu s i n g5 µL of the isolated
RNA. The reaction contained 25pmol of each of the primers
HIV1-Q3 and HIV1-Biot-Q4 (Table 1) that correspond to
the long terminal repeat (LTR) region of the HIV-1 genome,
Go Taq buﬀer, 1.5mM MgCl2, 250µMo fe a c hd N T P s ,3 . 6u
of AMV-RT, 9u of RNasin ribonuclease inhibitor, and 1.05u
of Go Taq Flexi DNA polymerase (all from Promega, USA).
The reaction was carried out in a thermocycler (Eppendorf,
Hamburg, Germany). The ampliﬁed productwas checkedby
hybridization using a probe complementary to the ampliﬁed
HIV-1 fragment (HIV1-S) (Table 1).
2.3. Ampliﬁcation of the Internal Control (IC) Fragment. A
fragment of 120bp was ampliﬁed by PCR, from a plasmid
that contained the sequenceofthe p-64Kprotein of Neisseria
meningitidis, ﬂanked by the sequences of binding to sense
and antisense primers (HIV1-Q3 and HIV1-Biot-Q4, resp.).
The PCR reaction was done using the same conditions
described above and the primers IC-1 and IC-2 (Table 1).
2.4. Cloning of the Ampliﬁed HIV-1 and IC Fragments into
the pGEM-T Vector. The ampliﬁed HIV-1 and IC fragments
were gel-puriﬁed using the Wizard SV Gel and PCR Clean-
Up System (Promega, USA) and cloned into the pGEM-T
vector following the manufacturer’s instructions (pGEM-
T and pGEM-T Easy Vector Systems, Promega, USA). Es-
cherichia coli XL-1 blue cells were transformed with the
products of the ligation reactions and plated on Luria-
Bertani- (LB-) ampicillin plate to select the transformed
colonies. The plasmid DNA was isolated and puriﬁed from
the colonies using the Wizard plus SV Minipreps DNA
Puriﬁcation System (Promega, USA), and PCR ampliﬁed to
check the orientation of the cloned HIV-1 and IC fragments.
The PCR reactions were performed using 25pmol of the T7
Promoter primer from Promega, USA (Table 1)a n d2 5p m o l
ofHIV1-Biot-Q4primer.ThecorrectorientationoftheHIV-
1 and IC fragments into the pGEM-T vector must generate a
PCR band of 189bp.
2.5. In Vitro Transcription. Two batches of the pGEM-HIV1
and pGEM-IC plasmids were linearized with Mlu1 enzyme
(Promega, USA). The correspondent HIV-1 and IC RNAs
were obtained from 1µg of pGEM-HIV1 and pGEM-IC
plasmids using 50u of T7 RNA polymerase (Promega, USA)
in presence of 0.75mM of each rNTPs (Promega, USA),
transcription buﬀer (Promega, USA) in a 50µLr e a c t i o n ,
according to the procedure optimized in our laboratory,
described in [19]. After transcription, 2 or 4u of RNase
free DNase (Promega, USA) per 1µg of template DNA, were
added for 15 or 30min at 37◦C to degrade the contaminant
DNA. Finally, the HIV-1 and IC transcripts were puriﬁed by
phenol-chloroformextraction and wereprecipitatedwith2.5
volumes of ethanol 95%. After RNA was washed and dried,
it was dissolved in 50µL of DEPC-treated water.Biotechnology Research International 3
2.6. Evaluation of the HIV-1 and IC Transcripts
2.6.1.DeterminationofRNA ConcentrationbyOptical Density
Measuring. One aliquot of each puriﬁed HIV-1 and IC
transcripts was diluted 1:20 or 1:35 with DEPC-treated
water and quantitated by measuring the optical density
(OD) at 260nm using the spectrophotometer (GeneQuant
II, Pharmacia, USA). The ratio of absorbance at 260 and
280nm was also obtained for the puriﬁed transcripts.
2.6.2. Evaluation of the Quality of the HIV-1 and IC Tran-
scripts by Determining the Presence of RNA and DNA Con-
tamination. The puriﬁed HIV-1 and IC transcripts were
diluted 1:4 in a lysis reagent for preservation at 4◦C[ 20,
21]. For the evaluation of the quality of the HIV-1 and
IC transcripts, they were 10-fold serially diluted in lysis
reagent from 1:4 × 103 to 1:4 × 109. Isolation of RNA
from lysis reagent was performed as described above. In
this case, the lysis reagent containing the HIV-1 and IC
transcripts was used in a volume of 500µLp e rs a m p l e .
To simulate the natural sample, in the case of transcripts
diluted in lysis reagent, 200µL of cryosupernatant negative
forhepatitisCvirus(HCV),human immunodeﬁciencyvirus
(HIV), and hepatitis B virus (HBV) were added to the
mixture. The absence of plasmid template and the presence
of RNA in the diluted HIV-1 and IC transcripts were veriﬁed
through 50 cycles of PCR and RT-PCR, respectively, in
mixes of 30µL, employing HIV1-Q3 and HIV1-Biot-Q4
primers. Several negative and positive RT-PCR and PCR
controls were tested. A HIV-, HCV- and HBV-negative
cryosupernatant was used as a negative control of each assay.
Positive HIV-1 RT-PCR control consisted on a positive HIV-
1 plasma sample while the positive HIV-1 and IC PCR
controls were the same plasmids used as templates in the in
vitro transcription reactions. The ampliﬁed products were
checked by hybridization using probes complementary to
HIV-1 (HIV1-S) and IC (IC-S1) fragments (Table 1).
2.6.3. Determination of the Working Dilution of the IC Tran-
script inanIn-HouseQuantitativeCompetitiveRT-PCRAssay.
The dilutionrequired forthe IC transcript to work optimally
as a competitor was determined by titration versus HIV-1-
positive human plasma calibration curves in a competitive
RT-PCR assay described below. The calibration curve was
obtained by diluting HIV-1-positive human plasma with
high viral load, 10-fold from 106 to 102 IU/mL. As internal
control, we evaluated four dilutions of the IC transcript,
using the lysis reagent as diluent (1:4 × 104,1:4× 105,1:4
× 106 and 1:4 × 107). Two HIV-1 RNA concentrations of
the WHO international standard (IS) 97/656 (NIBSC, South
Mimms, Potters Bar, Hertfordshire, UK) 103 and 104 IU/mL
were evaluated in the same experiment. Previously, each vial
of the international standard was reconstituted in 1mL of
ultrapurewaterasinstructedbytheNIBSCtoyieldasolution
containing 105 IU/mL of HIV-1 RNA. The determination
coeﬃcient r2, the curve slope (b) values, and the accuracy in
the quantiﬁcation of diﬀerent HIV-1 RNA IS concentrations
were taken into account to select the working dilution of the
IC transcript.
2.6.4. Determination of the HIV-1 Transcript RNA Concentra-
tion. The RNA concentration of the HIV-1 transcript was
determined through the qRT-PCR assay described below
using a calibration curve built from the IS 97/650 (NIBSC,
South Mimms, Potters Bar, Hertfordshire, UK). Each vial
of the international standard was reconstituted in 1mL
of ultrapure water as instructed by the NIBSC to yield a
solution containing 363 078.05IU/mL of HIV-1 RNA. It was
diluted 10-fold to obtain the calibration curve (363.08 to
363 078.05IU/mL). Isolation of RNAfrom IS or lysis reagent
containing the HIV-1 transcript was performed as described
above. The lysis reagent containing the IC transcript in its
working dilution was used in a volume of 500µLp e rs a m p l e .
The HIV-1 transcript was 10-fold serially dilutedfrom 1:4 ×
107 to 1:4 × 1011 in order to quantify it, and the RNA
concentration of the original HIV-1 transcript (IU/mL) was
obtained by averaging each value multiplied by the dilution
factor. HIV-1 transcript dilutions, where the R value was
out of the calibration curve range, were considered non
quantiﬁable.
2.6.5. Evaluation of the HIV-1 and IC Transcripts as Standards
in an In-House qRT-PCR Assay for Estimation of HIV-1
Viral Load. For standardization of the assay, the HIV-1
and IC transcripts were included as standards in an in-
house quantitative competitive RT-PCR assay for estimation
of HIV-1 viral load. The IC transcript is a 120-bp RNA
fragment, which is similar to the HIV-1 target except for a
short and unique internal sequence. This transcript is added
to the specimen during sample preparation and is simul-
taneously ampliﬁed by PCR in a competitive reaction. The
IC transcript was used into the lysis reagent in its working
dilution. In order to build the calibration curve, dilutions of
the HIV-1 transcript were made to give 103,1 0 4,1 0 5,1 0 6,
and 107 IU/mL of HIV-1 RNA. The IS was evaluated pure,
1:10, and 1:100, and also two samples with very high viral
load(HIV1-235andHIV1-157),previouslyquantiﬁedbythe
NucliSens EasyQ HIV-1 v1.1 assay (bioMerieux, Boxtel, The
Netherlands), were evaluated. Diﬀerent parameters such as
the determination of coeﬃcient r2 and the accuracy in the
quantiﬁcation of the HIV-1 RNA IS and the two reference
samples were measured.
2.7. Description of the In-House qRT-PCR Assay. Following
sample preparation and setup of the reaction mixture,
reverse transcription and ampliﬁcation of the target and
the internal control were simultaneously performed in the
same reaction tube. We added 5µL of the isolated RNA
to 25µLo fa nR T - P C Rr e a c t i o nm i x t u r et h a tc o n t a i n e d
50pmol of the HIV1-Q3 and HIV1-Biot-Q4 primers, Go
Taq buﬀer, 1.5mM MgCl2, 250µMe a c hd N T P s ,3 . 6 uo f
AMV-RT, 9u of RNasin ribonuclease inhibitor, and 1.05u
of Go Taq Flexi DNA polymerase (all from Promega,
USA). These reactions were carried out in a thermocycler
(Eppendorf AG 22331, Hamburg, Germany) at 45◦Cf o r
30min followed by 95◦C for 3min and 50 cycles at 95◦C
for 30s, 58◦Cf o r3 0s ,a n d7 2 ◦C for 30s. The hybridization
and detection of the ampliﬁed products were done in4 Biotechnology Research International
theultramicroenzyme-linkedoligosorbentassay(UMELOSA)
format [22]. It is a detection system similar to the one
u s e db yt h eA m p l i c o rH I V - 1M o n i t o rT e s tv 1 . 5 ,f r o mR o c h e
Diagnostic Systems (Branchburg, NJ, USA) [23], but unlike
the colorimetric reaction, we use a ﬂuorescence reading.
Following PCR ampliﬁcation, the HIV-1 and IC amplicons
were chemically denatured by the addition of denaturation
solution. Aliquotswere added, in duplicate, to separate wells
of a microwell plate coated with HIV-1-speciﬁc (HIV1-S)
an IC-speciﬁc (IC-S1) probes. HIV-1 and IC ampliﬁcation
products were bound to HIV-1 and IC wells, respectively,
by hybridization to the microwell plate-bound probes.
Following the hybridization reaction, the microwell plate
was washed to remove unbound material and a streptavidin-
alkaline phosphatase conjugate was added to each well of the
plate. The conjugate bound to the biotin-labeled amplicon
captured by the plate-bound probes. The plate was washed
again to remove unbound conjugate, and a substrate 4-
Methylumbelliferyl phosphate (4-MUP) was added to the
wells. In the presence of this ﬂuorescent substrate, the bound
alkaline phosphatase catalyzes the hydrolysis of 4-MUP to
producea ﬂuorescent signal that is detected by an automated
microwell plate reader.
The calibration curve, made from HIV-1 reference
sample, HIV-1 IS or HIV-1 transcript, was built by weighted
linear regression (WLR) [24] from the common logarithms
of theoretical viral loads (log10VLt ) and ratios of HIV-1 and
IC ﬂuorescence signals (log10R). HIV-1 RNA concentrations
of transcripts and samples were estimated by interpolating
log10R in the calibration curve.
2.8. Determination of the In-House qRT-PCR Limit of Detec-
tion. The 95% detection limit (LoD) or the sensitivity of the
in-house qRT-PCR assay was assessed on dilution series of a
WHO IS 97/656 (NIBSC, South Mimms, Potters Bar, Hert-
fordshire, UK). Each vial of the HIV-1 standard (subtype B)
was reconstituted in 1mL of ultrapure water as instructed by
the NIBSC to yield a solution containing 100000IU/mL of
HIV-1RNA.Itwasfurther dilutedin HIV-, HCV-,and HBV-
negative plasma, resulting in the following concentrations:
50, 100, 250, 500, 1000, 2500, and 5000IU/mL. The number
of replicas tested varied from 5 to 15, and they were run
in diﬀerent days with diﬀerent reagent lots and operators.
A HIV-, HCV-, and HBV-negative cryosupernatant was
included, as a negative control, in each run of the assay. We
employedthesametranscriptsandassayconditionsthatwere
used in Section 2.6.5. A positive result was considered when
thesample ﬂuorescencevaluewasthree-fold theﬂuorescence
value of the negative control. The LoD was estimated by
Probit analysis [9, 11, 25, 26], using SPSS version 9.0.
2.9.AnalysisoftheCorrelationbetweentheIn-HouseqRT-PCR
and NucliSens EasyQ Assays. We analyzed the correlation
between our in-house qRT-PCR assay and the commercial
NucliSens EasyQ HIV-1 v1.1 assay (bioMerieux, Boxtel, The
Netherlands) using linear regression analysis. The quantiﬁed
valuesof14clinicalplasmasamplesfromantiretroviral drug-
na¨ ıve and treatment-experienced patients were obtained
fromthe“PedroKour´ ı”TropicalMedicineInstitute(Havana,
Cuba), using the NucliSens EasyQ assay. We employed the
same transcripts and assay conditions that were used in
Section 2.6.5.
3.Resultsand Discussion
Because of HIV-1 variability, we selected and designed
primers and probes for the in-house qRT-PCR assay that
were based on a highly conserved LTR region of the HIV-1
genome. Instead of the gag gene, the use of the LTR
region extends the spectrum of detectable and quantiﬁable
genotypes beyond that of many current assays that are not
accurate for testing “exotic” HIV-1 subtypes found mainly in
developing countries [11].
TopreventPCRinhibition frominterfering withaccurate
quantiﬁcation, we designed a competitive internal control
that used the same ampliﬁcation primers as HIV-1 and was
detected by a probe of diﬀerent sequence composition.
We also optimized reaction chemistry to evaluate the
RNA standards and to quantify the IS and HIV-1 samples.
The ampliﬁed HIV-1and ICfragments were puriﬁedand
cloned into the pGEM-T vector. The presence of each band
intheTvectorwas checkedbyampliﬁcationusing theHIV1-
Q3 and HIV1-Biot-Q4 primers, and the fragment orienta-
tionwascheckedbyampliﬁcationusingtheT7Promoterand
HIV1-Biot-Q4 primers. In both cases, we obtained the PCR
band at the expected length, indicating the presence and the
correct orientation of the HIV-1 and IC fragments into the
pGEM-T vector.
The pGEM-HIV1 and pGEM-IC plasmids were in vitro
transcribed, and the resultant HIV-1 and IC transcripts (T-
HIV1 and T-IC, resp.) were puriﬁed. Before being diluted
in the lysis reagent, an aliquot of the two batches of each
transcript was diluted 1:20 or 1:35 and quantiﬁed by meas-
uring the OD at 260nm. RNA concentration in µg/mL was
obtained (Table 2).
According to McKenna et al. [14], large-scale in vitro
transcription of RNA yields varies with the transcript being
produced. Expected yields should fall in the range of 200–
1000µg/mL [14]. In one in vitro reaction, ARN concentra-
tion was below the lower limit of the expected range because
ofsome loss ofsample occurring during thepuriﬁcation step
of the T-IC second transcript. This issue has been described
by McKenna et al. during the phenol/chloroform extraction
of transcripts although they stated that this step is necessary
because far greater loss is incurred if the extraction step is
omitted [14]. Sample loss during RNA puriﬁcation, which
ratherdependsonthe technical skills oftheanalyst, allows us
to explain the big yield diﬀerences obtained among the same
transcript batches. In some cases, we obtained RNA yields
over the upper limit of the expected RNA concentration
range (Table 2). The ratio of absorbance at 260 and 280nm
(the A260/280ratio) is frequently used to assess the purity of
RNA and DNA preparations. A low A260/280 ratio indicates
contamination by proteins [27]. Data presented in Table 2Biotechnology Research International 5
Table 2: RNA concentration of the HIV-1 and IC transcripts determined by spectrophotometry at 260nm.
Transcript batch Dilution factor OD at 260nm (AU) A260/280 ratio RNA concentration (µg/mL)
T-IC-1a 20 0.550 1.556 440.0
T-IC-1b 20 0.793 1.614 634.4
T-IC-2a 35 0.118 1.586 165.2
T-IC-2b 35 0.817 1.664 1143.8
T-HIV1-1a 35 1.163 1.687 1628.2
T-HIV1-1b 35 0.225 1.665 315.0
T-HIV1-2a 35 0.471 1.543 659.4
T-HIV1-2b 35 1.183 1.700 1656.2
AU: absorbance units.
OD: optical density.
A260/280 ratio: the ratio of absorbance at 260 and 280nm.
aTranscript treated with 2u of RNase-free DNase per 1µgo fD N Au s e di nt h ein vitro transcription.
bTranscript treated with 4u of RNase free DNase-per 1µgo fD N Au s e di nt h ein vitro transcription.
Table 3: Evaluation of the presence of speciﬁc RNA (RT-PCR signal) and the DNA contamination (PCR signal) of the HIV-1 and IC
transcripts.
Name Dilution Average RT-PCR ﬂuorescence value (FU) ± SD Average PCR ﬂuorescence value (FU) ± SD
HIV-1-negative control — 4.05 ±0.09 3.56 ±0.18
HIV-1-positive control (RT-PCR) — 181.9 ±2.83 —
HIV-1-positive control (PCR) — — 117.80± 5.36
IC-negative control — 3.37 ±0.11 3.35 ±0.08
IC-positive control (PCR) — — 141.81± 2.14
T-HIV1-2b
1:4× 103 165.92 ±2.28 172.55± 8.15
1:4× 106 181.67 ±4.72 31.93± 0.17
1:4× 107 187.14 ±7.57 3.87 ±0.24
1:4× 108 170.72 ±8.42 3.87 ±0.03
1:4× 109 171.24 ±5.59 4.65 ±0.27
T-IC-2b
1:4× 103 210.00 ±03 .26 ±0.06
1:4× 106 107.55 ±0.36 3.35 ±0.04
1:4× 107 11.87 ±0.38 3.29 ±0.01
1:4× 108 3.43 ±03 .23 ±0.11
1:4× 109 3.46 ±0.11 3.43 ±0.03
bTranscript treated with 4 u of RNase-free DNase per 1 µgo fD N Au s e di nt h ein vitro transcription.
FU: ﬂuorescence units; SD: standard deviation; IC: internal control.
showed A260/280 ratios from 1.54 to 1.70. Similar results
were obtained by Okamoto and Okabe [27] when they used
D E P C - t r e a t e dw a t e rt od i s s o l v eR N Af o rp e r f o r m i n gt h e
spectrophotometric determinations. The authors stated that
DEPC-treated water did not aﬀect the absorbance at 260nm
b u te l e v a t e dt h a ta t2 8 0n m[ 27].
We also evaluated the quality of the HIV-1 and IC
transcripts. Transcripts with the highest RNA concentration
(T-IC-2b and T-HIV1-2b) were 10-fold serially diluted in
lysis reagent from 1:4 × 103 to 1:4 × 109. These dilutions
were subjectedtoRT-PCR toevaluatethepresenceofspeciﬁc
RNA and also subjected to direct PCR without RT in order
to test the DNA contamination. Neither PCR signal was
obtained for the IC transcript dilutions tested nor for the
highest dilutions of the HIV-1 transcript. Speciﬁc RT-PCR
signals were obtained for both transcripts (Table 3).
The use of RNA controls must be absolutely free of plas-
mid DNA carryover from the in vitro transcription reaction
[28]. Inthis sense, Hazari et al. [28] developedand evaluated
a competitive RT-PCR assay for HCV RNA in serum using
transcribed thioRNA as internal control. This internal
control RNA was tested for DNA contamination, and no
signal was obtained using 1µL of undiluted RNA,containing
108 molecules/µL[ 28]. Westerman et al. [29] developed a
quantitative reverse transcription-polymerase chain reaction
for measuring a marker for small cell lung carcinoma. A
standard curve was constructed from a complementary RNA
(cRNA) of the Human achaete-scute homologue 1 (HASH1)
protein that was obtained by in vitro transcription. The
authors demonstrated that complete removal of contami-
nating plasmid was essential for accurate quantiﬁcation, and
this was achieved by overnight incubation with RQ1 DNase
One during cRNA puriﬁcation [29].
In order to developan in-house qRT-PCR assay for HIV-
1 RNA and taking into account the very high yields that
are obtained in the in vitro transcription reactions [19],6 Biotechnology Research International
Table 4: Determination of the IC transcript (T-IC-2b) working dilution in a qRT-PCR assay.
T-IC-2b dilution r2 b Accuracy IS 103 IU/mL (Log10 VLt-Log10 VLe) Accuracy IS 104 IU/mL (Log10 VLt-Log10 VLe)
1:4× 104 0.14 −0.02 26.62 65.78
1:4× 105 0.87 0.31 −1.87 −3.05
1:4× 106 0.95 0.45 0.4 −0.45
1:4× 107 0.86 0.33 2.01 0.92
r2: determination coeﬃcient; b: curve slope; IS: HIV-1 RNA international standard (code 97/656); VLt: theoretical viral load; VLe: estimated viral load.
Table 5: Determination of the HIV-1 transcript (T-HIV1-2b) RNA concentration in a qRT-PCR assay.
Name T-HIV1-2b dilution HIV-1 RNA (IU/mL) Mean of the HIV-1 RNA (IU/mL)
T-HIV1-2b
1:4× 107 Non quantiﬁable
1.27E +1 4
1:4× 108 8.83E +13
1:4× 109 1.29E +14
1:4× 109 1.50E +14
1:4× 1010 1.02E +14
1:4× 1010 7.05E +13
1:4× 1011 2.21E +14
we used the dilutions of the transcript T-HIV1-2b in which
DNA signal was not obtained.
We determined the working dilution of the transcript T-
IC-2b which acts as internal control of an in-house qRT-PCR
assay for HIV-1 RNA. Several 10-fold dilutions of positive
HIV-1 human plasma were obtained for constructing a
calibration curve (102 to 106 IU/mL), and four dilutions of
the transcript T-IC-2b were evaluated.
As observed in Table 4, the dilution required for the IC
transcript to work optimally was 1:4 × 106,i nw h i c ht h e
r2 and the curve slope reached the maximum value. In the
selected IC working dilution, the qRT-PCR assay was able
to quantify the two IS concentrations (103 and 104 IU/mL)
accurately, with log10 diﬀerences below ±0.5log10 of the
expected units (Table 4). As discussed by some authors, a
minimally signiﬁcant change in plasma viremia is considered
to be a three-fold or 0.5log10 increase or decrease [30–32].
HIV-1 transcript was quantiﬁed so as to introduce it as
standard intheqRT-PCR assay. Forthispurpose, weused the
IS 97/650 to obtain the calibration curve and the transcript
T-IC-2b in its working dilution. Transcript T-HIV1-2b was
10-fold serially diluted from 1:4 × 107 to 1:4 × 1011 and
quantiﬁed using the calibration curve showed in Figure 1.
The RNA concentration estimated for the transcript T-
HIV1-2b was similar to the ones obtained by Gonz´ alez et al.,
in which the log10 orders of estimated HCV RNA concen-
trations were higher than 11 for all transcripts they obtained
[19]. In our study, we obtained HIV-1 RNA concentrations
about 1014 IU/mL (Table 5), allowing us to use the HIV-1
transcript as standard for quantiﬁcation purposes in cali-
bration curves that commonly have maximal concentrations
with log10 orders between 5 and 9 [19, 29].
HIV-1 and IC transcripts were included as standards
in an in-house qRT-PCR assay for estimating the HIV-
1 viral load from plasma samples. The calibration curve
was built from the HIV-1 transcript (T-HIV1-2b), and the
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Figure 1: Calibration curve from 3.63E +0 2t o3 .63E +0 5I U / m L ,
built from the HIV-1 RNA international standard (97/650) in lysis
reagent that contains the IC transcript (T-IC-2b)i ni t sw o r k i n g
dilution(1:4 ×106).LogR:commonlogarithmoftheratioofHIV-
1 and IC ﬂuorescence signals. WLR: weighted linear regression.
transcript (T-IC-2b) in its working dilution was used as
internal control. Diﬀerent HIV-1 RNA concentration of the
ISandtworeferenceplasmasampleswithveryhighviralload
were tested to evaluate the accuracy of the assay using these
HIV-1 controls.
Figure 2 shows the calibration curve obtained with the
inclusion of the HIV-1 and IC transcripts as standards. It
was obtained a regression line with an r2 = 0.99. All results
were found to be within ±0.5log10 unit of the expectedBiotechnology Research International 7
Table 6: Accuracy of the qRT-PCR assay by using HIV-1 controls and the transcripts as standards.
Sample HIV-1 RNA (IU/mL) Log10 expected results/actual results
Expected results Actual resultsc
IS (1:100) 3.63E +03 a 3.81E +03 −0.02
IS (1:10) 3.63E +04 a 4.81E +04 −0.12
IS 3.63E +05 a 5.78E +05 −0.20
HIV1-235 1.00E +06 b 2.33E +06 −0.37
HIV1-157 1.30E +06 b 1.03E +06 0.10
aThe value for each IS sample was obtained from dilutions made to the HIV-1 international standard (code 97/650) that contained 363 078.05IU/mL
(reconstituted in 1mL of ultrapure water) as instructed by the NIBSC manual.
bThe value for each material was determined by the NucliSens EasyQHIV-1 v1.1 assay (bioMerieux, Boxtel, The Netherlands).
cHIV-1 viral loads estimated from the in-house qRT-PCR assay using the HIV-1 (T-HIV1-2b)a n dI C( T - I C - 2 b) transcripts as standards.
Table 7: Determination of the lower limit detection (LoD) of the in-house qRT-PCR assay.
HIV-1 IS RNA concentrationsa (IU/mL) Number of replicas tested Positive results Positive rate (%)
5000 6 6 100
2500 6 6 100
1000 11 11 100
500 15 14 93.3
250 13 3 23.1
100 11 1 9.1
50 5 0 0
aThe HIV-1 IS RNA concentrations were obtained from dilutions made to the HIV-1 international standard (code 97/656) that contained 100000IU/mL
(reconstituted in 1mL of ultrapure water) as instructed by the NIBSC manual.
results (Table 6), which is considered not signiﬁcant for the
quantiﬁcation assay employed [30–32]. Similar results were
obtained by Muller et al., who evaluated ﬁve HIV-1 controls
from 102 to 5 × 104 copies/mL using a quantitative Abbott
LCx HIV RNA assay, and all results were found to be within
±0.32log10 unit of the expected results [31]. In order to
consider if a biological change in the viral load is signiﬁcant
or not, we show here the intra- and inter-assay variability
of the assay using three serum samples with diﬀerent viral
load values. These samples were repeated 24 times in this
precisionstudy.Precisionisdeﬁnedasthestandard deviation
of the log-transformed values [9]. In our study, intra-assay
precision was 0.3, 0.09, and 0.03log units at concentrations
2.7 × 103,2 . 6× 104,a n d2 . 0× 105 IU/mL, respectively.
Interassay precision was 0.43, 0.32, and 0.23log units at
concentrations 2.7 × 103,2 . 6× 104,a n d2 . 0× 105 IU/mL,
respectively. The intra-assay variability reported here was in
the range of that obtained for three commercially available
HIV-1 viral load assays, with reported values from 0.12 to
0.33logs [23]. De Mendoza et al. (2005) also reported intra-
assay precisionvaluesofapproximately0.17logunitsatHIV-
1 RNA concentrations above 1000IU/mL, and 0.26log units
for values lower than 1000IU/mL when they evaluated the
N u c l i S e n sE a s y QH I V - 1v 1 . 1a s s a y[ 9].
The percentage of positive results corresponding to each
HIV-1 RNA concentration tested by the in-house qRT-
PCR assay is shown in Table 7. Using Probit analysis, the
concentration of HIV-1 RNA with 95% detection was esti-
mated to be 511.0IU/mL (95% conﬁdence interval, 433.4–
588.6IU/mL). The LoD for the Amplicor HIV-1 Monitor
1.4
1.2
1
0.8
0.6
0.4
0.2
0
−0.2
−0.4
−0.6
−0.8
−1
2.5 3.5 4.5 5.5 6.5 7.5
o
g
R
Log (IU/mL of HIV-1 RNA)
y = 0.64x −3.07
r2 = 0.99
Original data
Data obtained by WLR
L
Figure 2: Calibration curve (1.27E + 03, 7.76E + 03, 1.65E + 05,
8.95E +05, and 9.39E + 06IU/mL) built from the HIV-1 transcript
(T-HIV1-2b) in lysis reagent that contains the IC transcript (T-IC-
2b) in its working dilution (1:4 × 106). LogR: common logarithm
of the ratio of HIV-1 and IC ﬂuorescence signals. WLR: weighted
linear regression.
test v1.5 (Roche Diagnostic Systems, Branchburg, NJ, USA)
using the standard specimen preparation procedure was
200copies/mL [33] or 312.5IU/mL if we take into account
the Roche conversion factor, 0.64 [34]. This Roche test is8 Biotechnology Research International
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Figure 3: Correlation between the NucliSens EasyQ HIV-1 v1.1
test (bioMerieux, Boxtel, The Netherlands) and the in-house qRT-
PCR assay, on 14 plasma specimens from HIV-1 infected patients.
The solid line represents the identity line, where all determinations
should fall if a perfect correlation between the two assays was
achieved. r2, determination coeﬃcient; r, correlation coeﬃcient.
based on a similar assay methodology to that ofourin-house
qRT-PCR assay.
The sensitivity obtained for our in-house qRT-PCR assay
was similar to the one obtained with the NucliSens EasyQ
HIV-1 (500.0IU/mL) using 0.2mL of input sample volume
[10, 32].
The analysis of correlation between our in-house qRT-
PCR assay and the NucliSens EasyQ HIV-1 test is shown in
Figure 3. The correlation between the two assays was high
(r = 0.925). A similar correlation coeﬃcient (r = 0.91) was
obtained by Choi et al., who compared the NucliSens EasyQ
H I V - 1v 1 . 1( b i o M e r i e u x )a n dR e a l T i m eH I V - 1( A b b o t t )k i t s
[1]. The correlation coeﬃcient of the NucliSens EasyQ HIV-
1 kit with the Cobas Amplicor HIV-1 Monitor v1.5 (Roche
Diagnostic Systems, Branchburg, NJ, USA) test, which is
based on traditional PCR method instead of real-time PCR,
was 0.87 [9].
A high correlation between diﬀerent assays is important
because the data on HIV-1 RNA quantitation are collected
from various laboratories using diﬀerent kinds of assay kits
nationwide [1]. However, it has been recommended using
the same method and also possibly the same laboratory to
monitor patients [35].
Human plasma or serum samples can be indistinctly
used in our in-house qRT-PCR assay because they were
both evaluated, and no signiﬁcant viral load diﬀerences were
found between them (data not shown).
It was observed a good linear behavior along the calibra-
tion curve built with the transcripts, which reached maxi-
mum HIV-1 RNA concentration near 107 IU/mL or 7log10
(Figure 2). As discussed by Yao et al., the ability to quantify
HIV-1 RNA over a 5log10 is important in this kind of assays
that are used toevaluateavariety ofpatientpopulationswith
a wide range of viral loads. This is an important asset when
a normal clinical laboratory test run includes samples from
newly diagnosed untreated patients, who generally have a
higher viral load than chronic HIV-1 infected adults. This
feature also eliminates the need for reﬂex repeat testing,
improves turnaround time for results, and is associated with
signiﬁcant savings in both technical time and reagent costs
[32].
In summary, the HIV-1 and IC transcripts were obtained
with the required quality to be used as standards for quan-
tiﬁcation purposes, considering also the advantage of their
long-term stability when stored in the lysis reagent [20, 21].
It was obtained a high correlation between our assay and a
commercial one. On the other hand, one of the major ben-
eﬁts of our method is cost reduction. Commercially assays
are currently oﬀered, even in developing countries, at prices
of approximately US $50–$100 per test [10, 11]. For our in-
house HIV-1 viral load assay, the net price would be reduced
considerably.
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